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Abstract
Background—Older individuals with inflammatory bowel disease (IBD) require ongoing 
medications. We aimed to describe 1) medication use in older and younger IBD patients and 2) 
medication associations with patient reported outcomes (PRO’s) in older patients.
Methods—We conducted cross-sectional and longitudinal analyses within CCFA Partners 
internet-based cohort of patients with self-reported IBD. We assessed medication use by disease 
sub-type and age. We used bivariate analyses to 1) compare medication use in older and younger 
patients and 2) determine associations between continued steroid use and PRO’s in older patients.
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Results—We included 5382 participants with IBD; 1004 were older (≥ age 60). Older patients 
with Crohn’s disease (CD) had lower anti-tumor necrosis factor alpha (anti-TNF) use at baseline 
(29.1% vs 44.3%, p<0.001), comparable steroid use (16.0% vs. 16.5%, p=0.77), and higher 
aminosalicylate use (40.3% vs. 33.9%, p=0.003) versus younger patients. Older ulcerative colitis 
(UC) patients had similar anti-TNF use (16.0% vs. 19.2%, p=0.16), lower steroid use (9.6% vs. 
15.4%, p=0.004) and higher aminosalicylate use (73.8% vs. 68.2%, p=0.04) at baseline. In 
longitudinal analyses, older CD patients had higher continued steroid use (11.6% vs. 7.8%, 
p=0.002); which was associated with worsened anxiety (p=0.02), sleep (p=0.01), and fatigue 
(p=0.001) versus non-use. Older CD patients on steroids, versus anti-TNF or immunomodulators, 
had increased depression (p=0.04) and anxiety (p=0.03).
Conclusions—Medication utilization differs in older patients with IBD. Older CD patients have 
higher continued steroid use; associated with worsened PRO’s. As in younger IBD populations; 
continued steroid use should be limited in older patients.
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Introduction
The populations of developed countries, such as the United States (US), are aging due to low 
fertility and mortality rates.1, 2 The 65+ age group is the fastest growing in the US with an 
estimated 31% increase over the past decade.3 In addition to an aging US population, 
inflammatory bowel disease (IBD) has a bimodal incidence distribution with 15% of cases 
occurring in the second peak, after 65 years of age.4 Due to these factors, the number of 
older patients living with IBD is expected to rise—including older persons newly diagnosed 
with IBD. Older-onset IBD may be associated with a milder disease phenotype with 
decreased progression to more severe stages such as stricturing or penetrating disease.5, 6 
Despite a milder phenotype, older IBD patients, regardless of age of onset, have higher 
resource utilization with increased rates of in-hospital morbidity and mortality compared to 
younger IBD patients.4 Therefore, optimizing the management of IBD in the older is 
increasingly important.7
Prior investigations have shown that the medical treatment strategies used in older IBD 
patients may be different compared to younger IBD populations, with an increased reliance 
on corticosteroids and 5-aminosalicylates (5-ASA) as maintenance therapies.8, 910 Steroid-
sparing strategies such as immunomodulators or biologic agents are used less frequently in 
older IBD patients in spite of current guidelines that support their use in this population for 
moderate to severe disease activity.9, 11, 12 Factors such as adverse effects from prolonged or 
repeated corticosteroid use and delay in the use of appropriate steroid sparing therapies 
related to disease activity may contribute to the lower short-term therapeutic efficacy and 
increased rates of adverse events seen in older IBD patients.4, 13, 14 The adverse effects of 
corticosteroid use among IBD patients have been well-established15, 16 including increased 
risks of serious infections, mortality, and accelerated bone loss, which are further potentiated 
when factoring in the independent risk factor of advanced age. However, it is unknown how 
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ongoing continued steroid use affects patient reported outcomes (PROs) such as anxiety, 
depression, sleep and fatigue in older IBD patients.
We used data from a large Internet-based study of IBD to describe current medical therapies 
in older IBD patients, rates of continued steroid use, and associations between continued 
steroid use and patient reported outcomes (PROs). Better information on the treatment 
experience of older IBD patients might aid in optimizing treatment strategies for this 
growing population.
Methods
CCFA Partners is an Internet-based prospective cohort study of over 14,000 adults living 
with self-reported IBD, including both CD and UC. The cohort initially began recruitment in 
2011. The details of cohort development have been previously described.17 Briefly, 
individuals with IBD are recruited to join CCFA Partners through social media, emails, 
advertising from the Crohn’s and Colitis Foundation of America (CCFA), CCFA events, and 
through physicians’ offices. Participants complete surveys every 6 months providing data on 
disease type, activity, course, medications, and selected PROs. Diagnoses in a randomly 
selected sample of the cohort have been validated, with over 96% of this sample having IBD 
confirmed by their physician.18 The surveys include a number of indices previously 
validated for self-report, including the short Crohn’s disease activity index (sCDAI),19 
simple clinical colitis activity index (SCCAI),20, 21 and short IBD questionnaire (SIBDQ).22
For the current analysis, we included all individuals who had completed at least 2 surveys 
over the course of a 12 month period (baseline and at least 1 follow-up) and whose disease 
type (CD or UC) had not changed over the course of the study time period. Those with 
indeterminate colitis (IC) were analyzed in the UC group. We used data from the baseline 
surveys to conduct a cross-sectional analysis of medication use, disease activity and other 
characteristics comparing older individuals (age ≥ 60 years) to younger individuals (age 18–
59 years). We then conducted two separate longitudinal analyses: (1) Comparisons of rates 
of long-term continued steroid use (defined as steroid use on 2 consecutive surveys at least 6 
months apart) in older versus younger individuals and (2) associations of continued versus 
non-continued steroid use with various health and quality related PRO’s among only older 
participants. Sensitivity analyses included an analysis of PRO’s in older IBD patients on 
continued steroid monotherapy as compared to biologic and/or anti-TNF therapy. To 
eliminate confounding by disease activity, a second sensitivity analysis evaluated the effects 
of continued steroid use on PRO’s restricted to those individuals who met criteria for 
remission at follow up. Remission was defined using a score of <150 on the sCDAI22 for 
patients with CD or a score of ≤2 on the SCCAI for patients with UC.20, 21 PRO’s were 
measured using five domains (anxiety, sleep disturbance, pain interference, fatigue, and 
depression) from the patient reported outcomes measurement information system (PROMIS) 
as previously described for this cohort.23 Briefly, all PROMIS measures have undergone 
rigorous development and validation in both general and chronically ill populations. Items 
are calibrated using a T-score metric with the mean of the US population equal to 50 and 
standard deviation (SD) of 10. Higher scores indicate “more” of the domain being measured, 
that is, worse anxiety, sleep disturbance, pain interference, fatigue, and depression. 
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Emerging data suggest than minimally important differences (MIDs) in PROMIS measures 
are in the range of 2 to 6,24 as suggested by our prior work in this cohort.23
Statistical Analysis
All analyses were performed using STATA 12.0 (College Station, TX). The population was 
characterized using descriptive statistics, including proportions, means, standard deviations, 
stratified by CD and UC. Outcomes were compared used bivariate statistics as appropriate. 
Confidence intervals were 95% and p<0.01 was considered statistically significant. The 
Institutional Review Board at the University of North Carolina at Chapel Hill approved the 
study protocol.
Results
Cross-Sectional Analyses of Baseline Surveys
A total of 5382 individuals with self-reported IBD were included. Of these, 3392 had CD 
and 1873 had UC/IC. Figure 1 shows geographic variation in corticosteroid use and biologic 
use for the entire cohort, with the highest overall use of biologics in patients with CD. There 
were 1004 older participants (≥60 years of age), 636 individuals with CD and 368 with UC. 
The median age for both the older CD and UC populations was 65 years. Characteristics of 
the CD and UC populations by age group are shown in Table 1 and Table 2 respectively.
Crohn’s disease
Older individuals with CD reported a higher rate of remission (64.2% vs 59.7%, p=0.05) 
determined by short Crohn’s Disease Activity Index (sCDAI) score < 150. Older CD 
individuals also reported a better health-related quality of life: Short Inflammatory Bowel 
Disease Questionnaire (SIBDQ) scores were 5.3 (IQR 4.5–6.0) versus 4.9 (IQR 3.9–5.7), 
p<0.001) at baseline. For CD patients, older participants had markedly higher rates of prior 
surgery (65.2% vs. 48.1%, p<0.001) compared to the younger participants. Within the CD 
population, there was no significant difference between use of corticosteroids between the 
older and younger populations (16.0% vs 16.5%, p=0.77). However, significantly fewer 
older CD individuals reported biologic anti-tumor necrosis factor-alpha (anti-TNF) use 
compared to younger CD patients (29.1% vs 44.3%, p<0.001). Aminosalicylate (5-ASA) use 
was higher amongst older CD patients as compared to younger (40.3% vs 33.9%, p<0.001).
Ulcerative colitis
The older versus younger UC populations reported similar rates of remission (45.9% vs 
43.9%, p=0.53) as determined by a SCCAI score of 2 or lower. Even with similar reported 
disease activity, older UC patients scored higher on the SIBDQ (5.5 (IQR 4.6–6.0) vs 5.0 
(IQR 4.0–5.8), p<0.001). Furthermore, surgery rates in the older population were similar to 
the younger population for UC (13.6% vs 11.8%, p=.35). Additionally, the older population 
reported lower corticosteroid use at baseline than younger patients (9.6% vs 15.4%, 
p=0.004). Differing from the CD population, the older UC patients had similar biologic anti-
TNF usage when compared to the younger UC patients (16.0% vs 19.2%, p=0.16). There 
was a small significant difference between rates of 5-ASA use among the older and younger 
UC populations (73.8% vs 68.2%, p=0.04).
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Longitudinal Analyses
In the longitudinal analyses, using data from both baseline and follow-up visits 6–12 months 
apart, prevalence of continued steroid use (current use reported at both time points) was 48% 
higher along older versus younger CD patients (11.6% vs. 7.8%, p=0.002). In contrast, 
continued use of biologic anti-TNF agents over this same time period was 60% lower in 
older CD participants, whereas prevalence of immunomodulator use was similar (Figure 2a). 
For UC patients, continued steroids, biologic anti-TNF agents and immunomodulators were 
all used less frequently by the older (Figure 2b).
Patient Reported Outcomes in Older Patients
We evaluated affects of continued medication use over 6–12 months on PROs measured at 
follow up. Among older patients, those with continued steroid use had significantly 
worsened anxiety (mean 52.5), sleep (mean 52.4) and fatigue (mean 55.3) as compared to 
non-steroid use. Pain (mean 53.9) and depression (mean 50.5) were also higher, albeit not 
statistically significantly when compared to non-steroid users. Similar effects were observed 
within strata of CD and UC participants. Differences in PRO’s overall and by disease 
subtype are shown in table 3. All comparisons that met statistical significant also met the 
threshold of ≥2, associated with a minimally important difference clinically. In a sensitivity 
analysis of only participants in remission at baseline, older patients with continued steroid 
use still had poorer health related quality of life scores in all 5 PROMIS domains when 
compared to non-users, although these differences were only significant for the fatigue 
domain (mean 52.2 vs. mean 48.2, p=0.02). In a separate analysis comparing older IBD 
patients on continued steroid monotherapy to older IBD patients on immunomodulators or 
biologic anti-TNF agents without steroids, those on continued steroids had significantly 
worsened depression (mean 50.8 vs. mean 48.2, p=0.03) and anxiety (mean 52.6 vs. mean 
49.8, p=0.04) at follow up.
Discussion
In a cross-sectional analysis, we found geographic differences in baseline medication 
utilization as well as differences between the older and younger CD and UC populations. 
Steroid use at baseline was similar between age groups for both CD and UC; however, 
biologic use was markedly lower for older patients with CD as compared to the younger 
population.
Lower rates of biologic use and higher 5-ASA use in older CD patients may suggest milder 
disease activity. This is supported by the higher rates of remission and better SIBDQ scores 
seen in this older CD population. However, despite these indicators supporting a milder 
disease activity, the reported GI surgery rates for both the older CD and UC populations 
suggest that disease activity may not be milder in the older. It is possible that providers are 
reluctant to prescribe biologic agents in this older population. Although biologic agents are 
highly effective, costs to the patient must be taken into account, especially for older patient 
populations on a fixed income. Per-patient yearly expenditure is estimated around $8,265–
$11,129 for CD, more costly than diabetes, stroke, coronary artery disease, chronic 
obstructive pulmonary disease, or multiple sclerosis.25–27 The lower rates of biologic use in 
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the older may be partially influenced by patients’ out of pocket expenses for these 
medications. It is also possible that concerns about safety of these agents in older patients 
may impact prescribing patterns.14, 28 Interestingly, older patients with CD had significantly 
higher rates of continued steroid use than younger populations in our longitudinal analysis—
perhaps related to these same factors of cost and perceived safety. In fact, corticosteroids, 
especially when used for more than 3 months duration, are considered potentially 
inappropriate medications (PIM) by the Beers Criteria. PIMs are associated with increased 
hospitalizations, costs of care, and mortality among older persons.29 Furthermore, it is 
important to note that steroids, not biologic anti-TNF agents or immunomodulators, have 
been associated with increased mortality in patients with IBD.15
Prior studies of medication utilization amongst the older IBD cohort indicate greater reliance 
on corticosteroids and 5-aminosalicylates as maintenance therapies.8, 9, 30 Biologic agents 
are used less frequently, in spite of literature supporting efficacy in moderate-to-severe CD 
and UC. Delays in starting appropriate steroid-sparing therapies may contribute to the 
potentially lower therapeutic efficacy seen in the few studies available, as well as the 
increased rates of adverse events.14 Higher rates of discontinuation associated with these 
medications in older patients may be due to poorer response rates but also may be due to 
evolving disease activity and declines in physical reserve. Consequences of prolonged 
disease activity (anemia, malnutrition, dehydration, etc) can be associated with increased 
infection risk and increased hospitalizations.4 Biologic agents have recently been associated 
with increased risks of adverse events in older patients with IBD, but this may be 
confounded by complications of disease activity.14 In contrast to data from IBD, the 
rheumatology literature does not describe differing rates of biologic anti-TNF use by age. 
Data from the anti-rheumatic drug intervention and utilization study (RADIUS) study, a 
real-world prospective observational program of rheumatoid arthritis patients aimed at 
assessing prescribing patterns, safety and effectiveness of disease modifying anti-rheumatic 
drugs (DMARDs) and biologics, showed similar rates of biologic prescribing for the older 
(≥ 65 years) and younger (<65 years) patients.31 Extrapolations from rheumatoid arthritis-
based studies focusing on the older population indicate an increased risk of serious infection 
and hospitalization with immunosuppression, but the safety signals are greater with 
corticosteroids and non-biologic DMARDs compared to anti-TNF based therapies.32, 33
Importantly, our study assessed the association of continued steroid use on important PROs 
in the older population. Given the effects we found on depressive symptoms, anxiety, 
fatigue, and sleep, continued steroid use should not be considered a “milder” treatment when 
compared to other forms of immunosuppression. These therapies directly impact a patient’s 
quality of life. These effects can have a greater impact even than well-known complications 
of corticosteroids including weight gain, bone health, metabolism, diabetes, and cataracts. 
These untoward effects can be particularly debilitating in an older population. Factors such 
as anxiety, fatigue, and depression negatively impact functional status. Declines in functional 
status in the older may result in increased disability, morbidity and cognitive impairment.34
The strengths of this cohort study include the geographically diverse and large sample size 
of participants in CCFA Partners, with members in every US state. As older patients are not 
well-represented in randomized controlled trials and are not necessarily seen in large 
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numbers at individual centers, this unique cohort allows for comparisons of important PROs 
in a large sample of older IBD patients. Additionally, within our cohort we are able to 
capture outcome data using validated instruments for self-report. There are also several 
limitations to this study. First, the patient volunteers who make up the CCFA Partners cohort 
are not necessarily representative of the IBD population of the US. Therefore, these findings 
may have limited external generalizability. As internet capability is required to participate, 
the CCFA Partners members may have higher education levels and socioeconomic status 
when compared to the IBD population in general. We also do not have access to pharmacy 
data or records of all prior medications and reasons for discontinuation. We did not collect 
data on steroid-specific physical manifestations such as striae, fluid retention, cataracts or 
fractures. We chose to focus on PRO’s instead, such as mood effects, sleep and fatigue, as 
these manifestations have not been systematically evaluated in a population of older patients 
on continued corticosteroids. We also do not have validation of all IBD diagnoses from 
within our cohort. However, in a validation study of a sample within CCFA Partners, over 
97% of individuals accurately reported their disease type when compared to records from 
their treating physician.35 Longitudinal data from within this cohort does have internal 
validity and the study design allows for optimal collection of PRO data.
In conclusion, older patients with IBD have different medication utilization patterns when 
compared to those of younger patients. There were large differences in biologic anti-TNF 
utilization in older versus younger CD patients. Continued steroid use was significantly 
higher in older CD patients and was negatively associated with important PROs. A better 
understanding of the complications of continued steroid use in this population will help 
drive age-specific guidelines for medication use. Ultimately, quality of life measures for 
older patients with IBD will be improved if continued steroid use can be minimized. With 
the aging of the IBD population, we need to understand the impact of our various therapies 
on both IBD activity and patient related outcomes.
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Figure 1. 
Baseline medication use by state within CCFA Partners by Crohn’s disease and ulcerative 
colitis
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Figure 2. 
Figure 2a: Continued* medication use in Crohn’s disease by age (n=3392)
*Defined by use at baseline and follow-up at least 6 months apart
Figure 2b: Continued* medication use in ulcerative colitis by age (n=1990)
*Defined by use at baseline and follow-up at least 6 months apart
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Table 1
Characteristics of CCFA Partner’s Crohn’s disease patients by age at baseline
Characteristics Older (age ≥ 60) (n=636)
Median (IQR) or %
Younger (age 18–59) (n=2756)
Median (IQR) or %
Age (years) 65 (62–70) 39 (29–50)
Gender (% female) 62.9 74.9
Education (% >high school) 90.9 91.7
Race (%)
 Caucasian 97.8 94.5
 African American 1.0 1.7
 Other 1.2 3.8
Current smoking (% yes) 6.2 7.8
BMI 25.1 (22.2–28.6) 23.9 (21.2–27.9)
Disease duration (years) 31 (13–42) 10 (4–21)
Ever GI surgery (% yes) 65.2 48.1
Ever GI hospitalization (% yes) 81.3 71.4
Number hospitalizations 4 (2–6) 3 (2–6)
Current medications (%)
 Biologic Anti-TNF 29.1 44.3
 Immunomodulator* 27.6 32.9
 Corticosteroids 16.5 16.0
 5-ASA& 40.3 33.9
Remission (sCDAI^ <150) (% yes) 64.2 59.7
sCDAI 114 (72–184) 128 (72–198)
SIBDQ** 5.3 (4.5–6) 4.9 (3.9–5.7)
*
Immunomodulator defined as 6-mercaptopurine, azathioprine, or methotrexate
&5-aminosalicylate
^Short Crohn’s disease activity index
**Short inflammatory bowel diseases questionnaire
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Table 2
Characteristics of CCFA Partner’s Ulcerative Colitis patients by age at baseline
Characteristics Older (age ≥60) (n=368)
Median (IQR) or %
Younger (age 18–59) (n=1622)
Median (IQR) or %
Age (years) 65 (63–70) 38 (29–48)
Gender (% female) 59.0 73.2
Education (% >high school) 90.9 93.9
Race
 Caucasian 97.3 91.9
 African American 1.2 1.2
 Other 1.5 6.8
Current smoking (% yes) 2.2 3.3
BMI 26.0 (23.3–29.4) 23.7 (21.3–27.4)
Disease duration (years) 16 (6–31) 7 (3–14)
Ever GI surgery (% yes) 13.6 11.8
Ever hospitalization (% yes) 39.7 47.4
Number hospitalizations 2 (1–3) 2(1–3)
Current medications
 Biologic Anti-TNF 16.0 19.2
 Immunomodulator* 18.5 24.0
 Corticosteroids 9.6 15.4
 5-ASA& 73.8 68.2
Remission (SCCAI^ ≤2) (% yes) 45.9 43.9
SCCAI 3 (1–4) 3 (1–5)
SIBDQ** 5.5 (4.6–6) 5 (4–5.8)
*
Immunomodulator defined as 6-mercaptopurine, azathioprine, or methotrexate
&5-aminosalicylate
^Simple clinical colitis activity index
**Short inflammatory bowel diseases questionnaire
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Table 3
Patient reported outcomes measured by PROMIS in older patients with IBD
Patient Reported Outcome Continued Steroid Use No Continued Steroid Use p value*
IBD overall (n=90) (n=871)
Anxiety 52.5 50.3 0.02
Sleep 52.4 50.1 0.01
Pain 53.9 50.9 0.07
Fatigue 55.3 51.6 0.001
Depression 50.5 48.8 0.07
Crohn’s disease (n=70) (n=535)
Anxiety 52.4 50.0 0.03
Sleep 52.3 50.6 0.11
Pain 53.1 50.9 0.25
Fatigue 55.7 52.6 0.02
Depression 50.8 48.7 0.05
Ulcerative colitis (n=20) (n=336)
Anxiety 52.9 50.7 0.31
Sleep 52.9 49.5 0.08
Pain 56.3 50.9 0.11
Fatigue 54.2 50.2 0.08
Depression 49.6 49.0 0.79
*
By student’s t-test
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